Medtronic has delivered four consecutive earnings beats on a foundation of near-perfect financial health metrics, but the stock is in a confirmed technical downtrend, options positioning signals unusual caution at a put/call ratio of roughly 5.7, and sole-source supplier dependencies represent a supply-chain vulnerability that limits conviction to add at current prices.
Thesis pillars
- Consistent Earnings Delivery→Stable
- Strong Financial Health Score→Stable
- Confirmed Technical Downtrend↑Improving
- +2 more pillars — see the Why tab for full reasoning
Medtronic plc. (MDT) Stock Analysis
Recovery setup · Catalyst-Driven edge
Healthcare · Medical Devices
Wait for pullback to $81.57. BUY gates pass at $91.20, but concentration risk — Supplier: sole suppliers and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $81.57 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum.
Medtronic is a global medical device company organized into four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — selling implantable and surgical therapies such as pacemakers, defibrillators, spinal implants, and insulin pumps to healthcare systems in... Read more
Wait for pullback to $81.57. BUY gates pass at $91.20, but concentration risk — Supplier: sole suppliers and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $81.57 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 77. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 17d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Medtronic plc.
About Medtronic plc.
Medtronic operates across four reportable segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — selling implantable and surgical medical devices to healthcare systems in more than 150 countries. The company employed over 95,000 full-time staff as of fiscal 2025, with 44% based in the U.S. or Puerto Rico, and in May 2025 announced its intention to separate the Diabetes Operating Unit into an independent, publicly traded company within 18 months.
Medtronic generates revenue by selling device-based therapies — pacemakers, defibrillators, cardiac ablation catheters, spinal implants, surgical stapling and energy systems, and insulin pumps — to hospitals and physicians who bill Medicare, Medicaid, private insurers, and comparable non-U.S. government programs for the associated procedures, making third-party reimbursement approval a gating factor for adoption. Manufacturing spans numerous company-owned facilities worldwide, supplemented by components, raw materials, and services purchased from numerous suppliers, though for reasons of quality assurance, cost effectiveness, or availability, certain components and services are obtained from sole suppliers. Growth has historically come from both internal research and development and acquisitions or investment collaborations that bring in new technologies, an approach the company continues to apply as it prepares to separate its Diabetes Operating Unit, which sells the MiniMed 780G insulin pump and Guardian Connect and Simplera continuous glucose monitoring systems, into a standalone public company.
Show full overview
A structural vulnerability sits inside Medtronic's supply chain: the 10-K discloses that for reasons of quality assurance, cost effectiveness, or availability, certain components, raw materials, and services needed to manufacture its products are obtained from sole suppliers, and several key products are manufactured or sterilized at a single facility with constrained capacity and limited alternate sterilization options. Because FDA licensing requirements slow the qualification of a replacement manufacturing or sterilization site, a facility closure or supplier failure could halt production of specific device lines faster than Medtronic could requalify an alternative source, a risk distinct from the broader input-cost pressure the filing also describes.
See also: Healthcare · Medical Devices
From Medtronic plc.'s most recent 10-K filing, extracted August 9, 2026.
Recent developments
updated 2026-08-15Recent Developments — Medtronic plc.
Latest news
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - simplywall.st — simplywall.st negative
- NEWS MDT Adds Rem700 Short Action Left Hand to CRBN Rifle Stock Lineup - Outdoor Wire — Outdoor Wire neutral
- NEWS Medtronic PLC $MDT Stock Position Decreased by California State Teachers Retirement System - MarketBeat — MarketBeat negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - Sahm — Sahm negative
- NEWS Is Medtronic’s (MDT) Pain-Portfolio Pivot Offsetting Quality Scrutiny From Its Pediatric Cannula Recall? - sahmcapital.c — sahmcapital.com negative
Generated 2026-08-15T13:12:18Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersole suppliers10-K Item 1A: 'certain components, raw materials and services needed to manufacture our products are obtained from sole suppliers.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $81.57. BUY gates pass at $91.20, but concentration risk — Supplier: sole suppliers and analyst target reached - limited upside remaining argue for a more patient entry. Engine's entry $81.57 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Chart setup: Death cross but MACD improving, RSI 77. Maintain position. Not compelling to add more. | News modifier +1 (HOLD_IF_HOLDING → STRONG_BUY_WAIT) Target $104.96 (+15.1%), stop $77.04 (−18.4%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Take-profit target: $104.96 (-2.9% upside). Target $104.96 (+15.1%), stop $77.04 (−18.4%), A.R:R -0.3:1. Stop-loss: $77.04.
Concentration risk — Supplier: sole suppliers; Analyst target reached - limited upside remaining; Overbought (RSI 77).
Medtronic plc. trades at a P/E of 24.3 (forward 14.2). TrendMatrix value score: 5.2/10. Verdict: Buy (Wait for Entry).
34 analysts cover MDT with a consensus score of 3.9/5. Average price target: $98.
What does Medtronic plc. do?Medtronic is a global medical device company organized into four segments — Cardiovascular, Neuroscience, Medical...
Medtronic is a global medical device company organized into four segments — Cardiovascular, Neuroscience, Medical Surgical, and Diabetes — selling implantable and surgical therapies such as pacemakers, defibrillators, spinal implants, and insulin pumps to healthcare systems in more than 150 countries. The company employs over 95,000 people and in May 2025 announced plans to separate its Diabetes Operating Unit into an independent public company.